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Abstract
Background: Previously, we have demonstrated a marked inhibition of codeine glucuronidation
by diclofenac in human liver tissue homogenate. We therefore aimed to investigate whether
diclofenac inhibits glucuronidation of codeine also in vivo in healthy volunteers.
Methods:  In a randomised, placebo-controlled, double-blind, cross-over study, 12 healthy
volunteers received a singe of 100 mg codeine phosphate plus 50 mg diclofenac sodium or codeine
phosphate plus placebo. Over a 36 hour period serum concentrations of codeine and its
metabolites as well as urinary excretion were analysed using LC-mass spectrometry. Side effects
were recorded and analgesic efficacy was determined using the cold pressor test (0–6 h).
Results: A single dose of diclofenac did not alter the formation of codeine-6-glucuronide in healthy
volunteers. Metabolic clearance of codeine to morphine was not affected by diclofenac. In terms of
side effects, both treatments were well tolerated. Diclofenac did not significantly influence the
analgesic effects of codeine in the cold pressor test.
Conclusions: In contrast to recent in vitro data, a single oral dose of diclofenac did not alter the
glucuronidation of codeine in healthy volunteers.
Background
The weak opioid codeine is widely used in the manage-
ment of pain. Various studies have demonstrated a syner-
gistic analgesic effect of an opioid-NSAID combination
[1–4], particularly if repeated doses are given. [5–7] The
synergistic effect is thought to be caused by the known dif-
ferent pharmacodynamic mechanisms, opioids acting via
opioid receptors in the central nervous system, NSAIDs af-
fecting the synthesis of prostaglandins due to inhibition
of the enzyme cyclooxygenase. NSAIDs have also been
postulated to display additional antinociceptive effects in
the central nervous system. [8] Moreover, a synergistic ef-
fect is also possible via a pharmacokinetic interaction be-
tween the two classes of drugs: NSAIDs may decrease the
renal excretion of the pharmacologically active metabolite
of morphine M-6-G (morphine-6-glucuronide).[9] We
have previously demonstrated a marked inhibition of co-
deine glucuronidation in human liver tissue homogenate
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by diclofenac (Ki of 7.9 µM).[10] Others have shown [11]
a more than 50% inhibition of the glucuronidation of the
codeine structural analogue, dihydrocodeine, by 50 µM
diclofenac in vitro. Codeine is predominantly metabo-
lised by glucuronidation to C-6-G (codeine-6-glucuro-
nide) (Figure 1). Minor metabolic pathways include N-
demethylation to norcodeine and O-demethylation to
morphine. [12,13] The latter is catalysed by the polymor-
phically expressed CYP2D6. [14–16] There is increasing
evidence, that the analgesic effect of codeine is mediated
by its O-demethylated metabolite morphine [17,18] and
that the glucuronidated metabolite M-6-G possesses even
greater analgesic potency than morphine itself.[19] In hu-
mans, the analgesic activity of C-6-G has not been report-
ed; however, antinociceptive responses after
intracerebroventricular administration have been report-
ed in rats. [20] Since in vitro findings may not necessarily
be of clinical relevance, we aimed to investigate whether
diclofenac inhibits codeine glucuronidation in vivo in
healthy volunteers in terms of pharmacokinetics, analge-
sic efficacy and side effects.
Methods
Subjects
Twelve healthy male volunteers, median age 31 years
(range 26–42 years), median weight 77 kg (range 63–95
kg), median BMI 23.9 kg/m2 (range 19.9–28.4 kg/m2)
participated in the study. One subject had to be replaced
because of additional drug intake during the study.
The study was approved by the ethics committee of the lo-
cal medical board (Landesärztekammer Baden Württem-
berg) according to the Declaration of Helsinki (1996
Sommerset). All volunteers gave their written informed
consent prior to study inclusion.
The volunteers were healthy according to history, physical
examination and laboratory tests, had no history of drug
abuse and did not take any regular medication. The volun-
teers had previously been genotyped for CYP2D6 by al-
lele-specific PCR [21,22] and all were predicted to be
extensive metabolisers (EM). In addition, the subjects
were phenotyped with respect to sparteine oxidation pol-
ymorphism with a single dose of 100 mg sparteine sul-
phate and were classified as EMs according to the
metabolic ratio (MR) of sparteine and its 2- and 5-dehy-
drometabolite.[23] In order to limit the effect of the vari-
ability of CYP2D6 on metabolic capacity, volunteers with
a MR<1 were generally included in the study, with one
subject having a MR of 2.8 (intermediate metaboliser).
Study design
The study was designed as a randomised, placebo-control-
led, double-blind, cross-over trial. Randomisation was
performed using the computer program Sampsize 2.0
(Blackwell Science Ltd., Machin, Campbell, Fayers, Pi-
nol). Each volunteer received on the study days 1 and 8 in
random order either 100 mg codeine phosphate + 50 mg
diclofenac sodium or 100 mg codeine phosphate + place-
bo. Codeine phosphate was provided as tablets (Codei-
num Phosphoricum forte Compretten®, Glaxo Welcome
GmbH/Cascan GmbH, Hamburg, Germany), diclofenac
sodium and placebo were provided as capsules of identi-
cal appearance (manufactured by Contract Pharma
GmbH & Co KG, Murr, Germany).
Blood and urine sampling
On study days 1 and 8 the following identical procedures
were carried out: Blood samples were taken before drug
administration as well as 0.25, 0.5, 0.45, 1, 1.5, 2, 2.5, 3,
4, 6, 8, 10, 12, 24, 35 and 36 hours after drug administra-
tion. Blood samples were centrifuged after 30 min. and se-
rum was stored at -20°C until analysed. Urine was
collected before drug administration and from 0–12, 12–
24 and 24–36 hours after drug administration. The vol-
ume was measured and an aliquot of each collection was
stored at -20°C until analysed.
Determination of analgesic effect
The analgesic effects of codeine with and without simulta-
neous administration of diclofenac or placebo were as-
sessed using the cold pressor test as previously
described.[17] Briefly, the cold pressor test apparatus con-
sisted of temperature-controlled water baths of 35 ± 0.5°C
and 1.0 ± 0.5°C (ice-water bath). The nondominant fore-
arm was placed into the warm-water bath for exactly 2
minutes. Fifteen seconds before transferring the forearm
into the cold-water bath, a blood pressure cuff was inflat-
ed to 20 mmHg below the diastolic blood pressure and
the eyes were covered with eye-patches. Subjects placed
their forearm in a fixed position with the fingers wide
Figure 1
The chemical structures of codeine and its major metabolites
in humans.
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apart into the cold-water bath (for a maximum time peri-
od of 2 min). They were instructed to clearly indicate the
time of the first pain sensation as well as the time of intol-
erable pain, at which the forearm was removed from the
cold-water bath. The time from the immersion of the fore-
arm into the cold-water bath to the first pain sensation
was measured, and is defined as the pain threshold. The
pain tolerance is defined as the time from immersion of
the forearm into the cold-water bath until the time of in-
tolerable pain. A training session was carried out before
the study to screen out volunteers with a pain tolerance of
less than 15 sec or more than 120 sec and to familiarise
the volunteers with the study procedure. The pain experi-
ments were conducted on study days before drug admin-
istration (10–15 min before drug administration) and 1,
1.5, 2, 2.5, 3, 3.5, 4 and 6 hours after drug administration.
Subsequently, the changes from baseline were determined
and for each study day the area under the pain threshold
change versus time curve and the area under the pain tol-
erance change versus time curve were calculated.
Determination of adverse events
Adverse events were evaluated by the following method:
The volunteers were required to list each symptom (fa-
tigue, headache, dizziness, blurred vision, nausea, itching,
exanthema and any other symptom) on a visual analogue
scale (VAS) rated from 0 (not present) to 10 (most severe)
at zero h (baseline, before drug intake), 2, 4 and 6 hours
after drug intake. The values were corrected for the base-
line measurement at t = 0 h.
Analytical measurement of codeine and its metabolites
Codeine and its metabolites were determined using
HPLC-electrospray mass spectrometry analogous to a pre-
viously published method[24] with minor modifications.
Samples (1.0 ml of plasma, or 100 µl of urine diluted with
900 µl of water) were spiked with the deuterated internal
standards (10 µl of standard mix with 50 pmol/µl co-
deine-G-glucuronide-d3, 5 pmol/µl codeine, 10 pmol/µl
morphine-3-glucuronide-d3, 5 pmol/µl morphine-6-glu-
curonide-d3 and 1 pmol/µl morphine-d3) and extracted
automatically using end-capped C2 solid-phase extraction
columns. For the determination of the conjugates of nor-
codeine and normorphine, urine was hydrolysed[25] pri-
or to extraction. The mobile phases used for HPLC were:
(A) 1 % acetic acid in water and (B) 1 % acetic acid in ac-
etonitrile. HPLC separation was achieved on a Li-
Chrospher 100 RP-18 (Merck, Darmstadt, Germany) end-
capped analytical column (125 ×  3 mm I.D., 5 µm particle
size) at a flow rate of 0.5 ml/min using a linear gradient
from 8 % B to 40 % B in 8 min. The mass spectrometer
(HP 1100 MSD, Hewlett-Packard, Waldbronn, Germany)
was operated in the selected ion monitoring mode using
the respective MH+ ions, m/z 476 for codeine-6-glucuro-
nide, m/z 300 for codeine, m/z 303 for codeine-d3, m/z 286
for norcodeine, m/z 462 for morphine-3-glucuronide and
morphine-6-glucuronide and m/z 465 for the deuterated
morphine glucuronides, m/z 286 for morphine, m/z 289
for morphine-d3 and m/z 272 for normorphine. The limits
of quantification achieved with this method were 0.5
pmol/ml for the morphine-glucuronides and morphine, 2
pmol/ml for codeine, normorphine and norcodeine and
5 pmol/ml for codeine-6-glucuronide with coefficients of
variation less than 12 %.
Analytical measurements of diclofenac
Following the addition of 100 µl of a 10 µg/ml solution of
4'-methoxydiclofenac in water for internal standardisa-
tion and 2 ml 10 mM phosphate buffer pH 6.5 to 1 ml of
serum, samples were extracted by an automated solid
phase extraction procedure using an ASPEC XL (Gilson,
Villiers Ie Bel, France). Samples were applied on Baker-
bond SPE™ C18 extraction columns (3 ml, 500 mg) which
were equilibrated with 3 ml methanol and 3 ml of phos-
phate buffer. The columns were washed with 2 ml of
phosphate buffer and 2 ml of phosphate buffer: methanol
6:4 (v/v) and eluted with phosphate buffer: methanol 2:8
(v/v). The solvents were evaporated and the residue was
resuspended in 150 µl of the mobile phase. A 100 µl aliq-
uot was injected on a HPLC-system consisting of an au-
tosampler SIL 9A, a solvent delivery system LC 9A and an
UV-detector (Shimadzu, Duisburg, Germany). Separation
was performed on a Waters Spherisorb ODS1 5 µm 125 ×
4.6 mm column equipped with a guard column filled
with the same material (Bischoff, Leonberg, Germany) us-
ing 8 mM tetrabutylammonium bromide in 10 mM phos-
phate buffer pH 6.5:acetonitrile:tetrahydrofuran 65:30:5
(v/v/v) at a flow rate of 1 ml/min. Diclofenac and the in-
ternal standard 4'-methoxydiclofenac were detected at
282 nm at a retention time of 11.0 and 12.4 min, respec-
tively. Recovery was between 85 and 100.5%. Calibration
curves were linear over a concentration range from 10 to
2000 ng/ml (r2 ranging from 0.9993 to 1). Inter-assay var-
iability (n = 9) was 14.2, 8.3, and 7.8% for 30, 300, and
2000 ng/ml, respectively. Accuracy was within 10% at
these concentrations.
Pharmacokinetic evaluation
Standard noncompartmental analysis for calculations us-
ing serum concentration-time data was performed using
TOPFIT 2.0 (Gustav Fischer Verlag 1993).
The following pharmacokinetic parameters were deter-
mined from serum concentration-time data and urine
concentration data for codeine (cod), codeine-6-glucuro-
nide (C-6-G), norcodeine (NC), morphine (morph), mor-
phine-3-glucuronide (M-3-G), morphine-6-glucuronide
(M-6-G) and normorphine (NM):BMC Clinical Pharmacology 2002, 2 http://www.biomedcentral.com/1472-6904/2/2
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Cmax- peak serum concentration [pmol ml-1], obtained
from the visual inspection of the serum concentration-
time curves
tmax- time to reach peak serum concentrations [h], ob-
tained from the visual inspection of the serum concentra-
tion-time curves
t1/2- terminal phase half-life [h] calculated according to
ln(2)/λ z, the terminal elimination rate constant λ z was de-
termined from the slope of the regression line of In(con-
centration) vs time
AUC0-∞ - area under the serum concentration curve [pmol
ml-1*h], calculated by the trapezoidal rule, the segment to
infinity was calculated from the last concentration meas-
ured by dividing the last concentration measured by the
elimination rate constant (λ z)
ratio AUC' s- AUC0-∞  codeine/AUC0-∞  morphine
Ae- cumulative amount of codeine, C-6-G, norcodeine,
norcodeine-glucuronide, morphine, M-3-G, M-6-G, nor-
morphine and normorphine-glucuronide [% of dose] ex-
creted in urine
CLo- apparent oral clearance of codeine calculated using
dose/AUC0-∞  [ml min-1]
CLcod→ c-6-G- metabolic clearance of codeine to C-6-G cal-
culated as Ae C-6-G/AUC0-∞  codeine [ml min-1]
CLcod→ NC- metabolic clearance of codeine to norcodeine
calculated as (Ae norcodeine + Ae norcodeine-glucuro-
nide)/AUC0-∞  codeine [ml min-1]
CLcod→ morph- metabolic clearance of codeine to mor-
phine calculated as (Ae morphine + Ae M-3-G + Ae M-6-G
+ Ae normorphine + Ae normorphine-glucuronide)/
AUC0-∞  codeine [ml min-1]
CLmorph→ M-3-G- metabolic clearance of morphine to M-3-
G calculated as Ae M-3-G/AUC0-∞  morphine [ml min-1]
CLmorph→ M-6-G- metabolic clearance of morphine to M-6-
G calculated as Ae M-6-G/AUC0-∞  morphine [ml min-1]
CLmorph→ NM metabolic clearance of morphine to nor-
morphine calculated as (Ae normorphine + Ae normor-
phine-glucuronide)/AUC0-∞ morphine [ml min-1]
CLren cod- renal clearance of codeine calculated as Ae co-
deine/AUC0-∞  codeine [ml min-1]
CLren morph- renal clearance of morphine calculated as Ae
morphine/AUC0-∞  morphine [ml min-1]
CLren C-6-G- renal clearance of C-6-G calculated as Ae C-6-
G/AUC0-∞  C-6-G [ml min-1]
CLren NC- renal clearance of norcodeine calculated as Ae
norcodeine/AUC0-∞  norcodeine [ml min-1]
CLren M-3-G- renal clearance of M-3-G calculated as Ae M-
3-G/AUC0-∞  M-3-G [ml min-1]
CLren M-6-G- renal clearance of M-6-G calculated as Ae M-
6-G/AUC0-∞  M-6-G [ml min-1]
CLren NM- renal clearance of normorphine calculated as Ae
normorphine/AUC0-∞  normorphine [ml min-1]
Statistical analysis
In this cross over study, 12 subjects were required to en-
sure a 80% power of detecting a potentially clinically rel-
evant difference in pharmacokinetic parameters of 30%
with a variability of 25% at the 5% significance level for α .
Pharmacokinetic data are presented as mean ± 95% CI.
Pharmacokinetic data of codeine and its metabolites after
administration of codeine + placebo vs. codeine + di-
clofenac are compared using the Wilcoxon matched pairs
test. In addition, AUC and Cmax of codeine and C-6-G
were investigated in terms of bioequivalence: Point esti-
mates (geometric means) and 90% CI were given for the
ratios test/reference (test: pharmacokinetic parameters
under consideration after codeine + diclofenac, reference:
pharmacokinetic parameters under consideration after co-
deine + placebo). Test was considered bioequivalent to
reference if 90% CI of log transformed AUC ratios were
within 0.80–1.25 and Cmax ratios were within 0.75–1.34.
Adverse events are presented in two different manners: 1.)
The number of subjects reporting any side effect after ad-
ministration of codeine + placebo vs. codeine + diclofenac
were compared using the chi square test. 2.) At different
time points (2, 4 and 6 h after drug administration) VAS-
rated mean sum scores of all reported side effects after ad-
ministration of codeine + placebo vs. codeine + diclofenac
were calculated; the mean sum scores are compared using
the paired Wilcoxon matched pairs test at the different
time points. The area under the pain threshold versus time
curve and the area under the pain tolerance versus time
curve (corrected to baseline at t = 0 h) are presented as
mean ± SD and are compared using Wilcoxon matched
pairs test. A p value of less than 0.05 was considered sig-
nificant.BMC Clinical Pharmacology 2002, 2 http://www.biomedcentral.com/1472-6904/2/2
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Results
Pharmacokinetic data
Similar serum concentrations of codeine and its metabo-
lite C-6-G were observed after treatment with codeine +
placebo vs. codeine + diclofenac (Figure 2). Peak serum
concentrations (Cmax) of codeine (764; 602–924 pmol
ml-1 vs. 821; 663–980 pmol ml-1) and C-6-G (5263;
4738–5788 pmol ml-1 vs. 5621; 5167–6074 pmol ml-1),
did not differ significantly between the two different treat-
ments, nor did the time to attain peak serum concentra-
tions (tmax) and the terminal half-life t1/2 (Table 1). The
concentrations of codeine and its metabolites in the one
intermediate metaboliser (MR = 2.8) were within the
range of the concentrations of the other volunteers with
MR<1, however as expected the metabolites formed via O-
demethylation (morphine, morphine glucuronides and
normorphine) were the lowest or second lowest observed.
The AUCs of codeine did not differ between the two treat-
ments (Table 2). In addition, the two treatment, based on
AUCs and Cmax of codeine and C-6-G, could be consid-
ered bioequivalent: Point estimates of the test/reference
ratios and 90% CI were 1.007 (0.998–1.017) for AUC co-
deine, 1.004 (1.001–1.008) for AUC of C-6-G, 1.015
(0.990–1.042) for Cmax of codeine and 1.008 (1.001–
1.016) for Cmax of C-6-G. However, a small but significant
increase in the AUC of C-6-G (+ 5.5%) was observed in
subjects after codeine + diclofenac (Table 2). In terms of
morphine formation, the ratios of AUC codeine/AUC
morphine did not reveal a significant difference (53.4;
10.5–96.4 95% CI vs. 45.2; 16.4–74.0 95% CI) between
the two treatments.
Peak serum concentrations (Cmax) of morphine (22.4
pmol ml-1; 12.3–32.5 95% CI vs. 24.3 pmol ml-1; 13.7–
35.0 95% CI) and M-6-G (63.4 pmol ml-1; 38.7–88.1
95% CI vs. 68.8 pmol ml-1; 41.2–96.5 95% CI) did not
differ significantly between the two different treatments,
as well as the time to attain peak serum concentrations
(tmax) and the terminal half-life t1/2 (Table 1). AUC of
Table 1: Time to attain peak serum concentrations (tmax) and terminal half-life of codeine and its metabolites (n = 12).
codeine + placebo mean (95% CI) codeine + diclofenac mean (95% CI) p level
tmax codeine [h] 0.69 (0.51–0.87) 0.71 (0.51–0.91) n.s.
Cmax codeine [pmol/ml] 764 (602–924) 821 (663–980) n.s.
t1/2 codeine [h] 3.37 (3.16–3.59) 3.43 (3.24–3.62) n.s.
tmax C-6-G [h] 1.13 (0.89–1.35) 1.10 (0.87–1.34) n.s.
Cmax C-6-G [pmol/ml] 5263 (4738–5788) 5621 (5167–6074) n.s.
t1/2 C-6-G [h] 3.54 (3.39–3.68) 3.54 (3.36–3.73) n.s.
tmax morphine [h] 0.63 (0.45–0.80) 0.67 (0.53–0.81) n.s.
Cmax morphine [pmol/ml] 22.4 (12.3–32.5) 24.3 (13.7–35.0) n.s.
t 1/2 morphine [h] 8.78 (5.97–11.59) 8.54 (6.74–10.61) n.s.
tmax M-6-G [h] 1.5 (1.37–1.64) 1.35 (1.06–1.65) n.s.
Cmax M-6-G [pmol/ml] 63.4 (38.7–88.1) 68.8 (41.2–96.5) n.s.
t1/2M-6-G [h] 7.77 (7.40–8.13) 8.10 (7.57–8.63) n.s.
Table 2: Area under the serum concentration time curve (AUC0-∞ ) of codeine and its metabolites (n = 12).
[pmol ml-1*h] codeine + placebo mean (95% CI) codeine + diclofenac mean (95% CI) p level
AUC codeine 2416 (2025–2807) 2515 (2176–2855) n.s.
AUC C-6-G 29550 (26190–32910) 31120 (28150–34090) < 0.05
AUC norcodeine 342 (257–428) 338 (228–448) n.s.
AUC morphine 94.5 (52.9–136) 92.1 (53.8–131) n.s.
AUC M-3-G 2137 (1298–2976) 2259 (1427–3091) n.s.
AUC M-6-G 425 (254–596) 471 (298–644) < 0.05
AUC normorphine 540 (396–684) 549 (387–710) n.s.BMC Clinical Pharmacology 2002, 2 http://www.biomedcentral.com/1472-6904/2/2
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morphine did not differ between the two treatments (Ta-
ble 2). A small but significant increase of the AUC of M-6-
G (+10.8%) was observed after codeine + diclofenac (Ta-
ble 2). Serum concentration-time curves of morphine, M-
3-G and M-6-G are displayed in Figure 3.
No significant differences were observed in either the ap-
parent oral clearance of codeine (CLo) (1805 ml min-1;
1498–2112 95% CI vs. 1700 ml min-1; 1470–1929 95%
CI), metabolic clearance of codeine to C-6-G, norcodeine
and morphine, of morphine to M-3-G, M-6-G and nor-
morphine or renal clearance of codeine and its metabo-
lites between the two treatments (Tables 3 and 4). The
total amount excreted of codeine and its metabolites ex-
creted was 81.3% of dose (76.3–86.3 95% CI) vs. 84.9%
of dose (81.8–88.0 95% CI) and did not differ between
the two treatment groups. The urinary recoveries of co-
deine and its metabolites are listed in Table 5.
Diclofenac was detected in the serum of all subjects after
codeine + diclofenac with mean peak serum concentra-
tion of 4.4 nmol/ml (3.77–5.06 95% CI) after 1.73 h
(1.21–2.26 95% CI) (see Table 6).
Pharmacodynamic data and adverse events
The area under the pain threshold-time as well as the area
under the pain tolerance-time curves did not differ signif-
icantly after administration of codeine + placebo vs. co-
deine + diclofenac (8.68 ± 12.7 vs. 4.87 ± 9.82 s*h and
23.3 ± 57.5 vs. 13.9 ± 35.6 s*h, respectively). The time
courses of pain threshold and pain tolerance are displayed
in Figure 4.
Both codeine + placebo and codeine + diclofenac were
well tolerated by the volunteers. Only minor side effects
occurred and no rating higher than 5 was reported on a
VAS scale. The number of subjects reporting any adverse
event from VAS rated from 0 (not present) to 10 (most se-
vere) at 2, 4 and 6 hours after drug intake is displayed in
table 7 and did not differ significantly between the two
treatments. Also, no significant differences could be ob-
served concerning the mean sum scores of all reported
side effects at the given time points (Table 8).
Discussion
The possible pharmacokinetic interaction between co-
deine and diclofenac could have clinical implications:
One could have speculated that by inhibiting codeine glu-
curonidation other metabolic pathways of codeine, espe-
cially O-demethylation to morphine may then be
favoured in extensive metabolizers of CYP2D6, resulting
in elevated morphine serum levels and a greater analgesic
effect, and, possibly also increased adverse effects. A direct
influence of diclofenac on O-demethylation of codeine to
morphine via interaction with CYP2D6 has been exclud-
ed.[26]
Considering our previous in vitro data[10], it was impor-
tant to verify whether codeine glucuronidation was inhib-
i t e d  b y  d i c l o f e n a c  i n  v i v o  a f t e r  a d m i n i s t r a t i o n  o f  a
commonly used dose.
However, after single dose administration of codeine + di-
clofenac in healthy volunteers we did not observe major
changes in the pharmacokinetics of codeine and its me-
tabolites compared to codeine + placebo. In this study, co-
deine and diclofenac were given in a dose commonly used
for clinical treatment of pain. In addition, no significant
differences in the ratios AUC codeine/ AUC morphine
were detected after the two different treatments, indicat-
ing that the formation of morphine from codeine re-
mained unaffected. A slight increase in the AUCs of C-6-G
(+5.5%) and M-6-G (+10.8%) after the diclofenac con-
taining regimen was observed, reaching statistical signifi-
cance (p < 0.05). This might be a result of inhibition of
renal excretion of both glucuronides by diclofenac or its
glucuronide. In our opinion, these minor changes are not
of clinical relevance after single dose administration. Nev-
ertheless, the observed non significant decrease in renal
clearance especially of M-6-G in the diclofenac containing
regimen, might play a role during chronic treatment with
opioids.
Figure 2
Serum concentration time profile of codeine and codeine-6-
glucuronide after administration of codeine + placebo vs.
codeine + diclofenac (Mean, SD, n= 12)  codeine + placebo
♦  codeine + diclofenac
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In this study, we did not investigate a possible influence
of codeine on the pharmacokinetics of diclofenac because
it has been previously demonstrated that codeine does
not influence the relative bioavailability of diclofenac in
vivo.[27] The pharmacokinetic results obtained from this
study do not confirm our previous in vitro data with hu-
man liver tissue homogenates, which revealed a marked
non-competitive inhibition of codeine-6-glucuronidation
caused by diclofenac (Ki of 7.9 µM in a concentration
range of 100–10000 µM codeine and 0.5–100 µM di-
clofenac).[10] Although UGT (UDP-glucuronosyltrans-
ferase) 2B7, the UGT catalysing codeine-6-
glucuronidation, morphine-6-glucuronidation and di-
clofenac glucuronidation [28], is known to be expressed
in the intestine,[29] we did not favour a potential interac-
tion of codeine-6-glucuronidation at the level of the small
intestine because of its very low intrinsic clearance com-
pared to liver tissue in vitro.[10]
Table 3: Partial metabolic clearances of codeine and morphine after administration of 100 mg codeine phosphate (n = 12).
Clmet [ml min-1] codeine + placebo mean (95% CI) codeine + diclofenac mean (95% CI) p level
codeine →  C-6-G 1134 (882–1385) 1104 (928–1279) n.s.
codeine →  morphine 174 (118–230) 176 (126–226) n.s.
codeine →  norcodeine 102 (69.1–136) 97.1 (76.2–118) n.s.
morphine →  M-3-G 2631 (1227–4036) 2550 (1527–3573) n.s.
morphine →  M-6-G 702 (362–1042) 692 (446–938) n.s.
morphine →  normorphine 3090 (431–5749) 2600 (1456–3744) n.s.
Table 4: Renal clearances of codeine and metabilites after administration of 100 mg codeine phosphate (n = 12).
Cl ren [ml min-1] codeine + placebo mean (95% CI) codeine + diclofenac mean (95% CI) p level
codeine 66.5 (54.6–78.3) 64.2 (53.6–74.9) n.s.
C-6-G 88.6 (76.4–101) 86.6 (78.6–94.5) n.s.
norcodeine 220 (187–253) 233 (208–259) n.s.
morphine 117 (72.4–162) 114 (83.6–144) n.s.
M-3-G 88.2 (76.1–100) 86.2 (77.1–95.4) n.s.
M-6-G 122 (108–136) 114 (101–127) n.s.
normorphine 123 (106–141) 133 (115–152) n.s.
Table 5: Urinary excretion of codeine and metabolites after administration of 100 mg codeine phosphate (n = 12).
Ae [% of dose] codeine + placebo mean (95% CI) codeine + diclofenac mean (95% CI) p level
codeine 3.74 (3.33–4.15) 3.89 (3.10–4.68) n.s.
C-6-G 62.2 (57.0–67.5) 64.7 (60.7–68.7) n.s.
norcodeine 1.76 (1.35–2.18) 1.86 (1.36–2.36) n.s.
norcodeine-glucuronide 3.87 (3.01–4.73) 4.01 (3.02–5.00) n.s.
morphine 0.22 (0.13–0.32) 0.23 (0.14–0.33) n.s.
M-3-G 4.40 (2.81–5.99) 4.66 (3.10–6.22) n.s.
M-6-G 1.21 (0.77–1.64) 1.31 (0.83–1.78) n.s.
normorphine 1.56 (1.91–1.93) 1.73 (1.34–2.11) n.s.
normorphine-glucuronide 2.30 (1.80–2.79) 2.50 (1.99–3.01) n.s.BMC Clinical Pharmacology 2002, 2 http://www.biomedcentral.com/1472-6904/2/2
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The pharmacokinetic data for codeine and its metabolites
obtained in our study are supported by the data obtained
by other investigators.[12,13,30] The codeine peak serum
concentrations observed in our study ranged from 517 to
1481 pmol ml-1 and therefore did not reach the concen-
trations used in our previous in vitro investigation.
Kirkwood et al. could demonstrate a more than 50% inhi-
bition of the glucuronidation of the codeine structural an-
alogue dihydrocodeine by 50 µM diclofenac. [11] In our
study, mean peak serum concentrations of diclofenac
were 4.4 nmol/ml (range 3.01–6.21 nmol/ml) and were
in the same range as reported by Davies et al.[31] Mean
tmax of diclofenac was 1.73 h, so peak serum concentra-
tions of diclofenac were later than the tmax of C-6-G and
M-6-G (table 1). In addition, diclofenac is known to be
highly bound to serum protein (>99.7%).[31] Therefore it
is likely that diclofenac, at least after administration of a
common single dose, does not achieve serum levels fast
enough and high enough to inhibit codeine glucuronida-
tion in vivo. Furthermore, it is unlikely that a multiple
dose regimen of diclofenac (e.g. 50 mg tid) would lead to
the cumulation of diclofenac serum levels due to the short
elimination half-life of diclofenac (mean t1/2 0.97 h in
our study). Therefore, in our opinion, steady-state admin-
istration of diclofenac will also not alter codeine glucuro-
nidation in vivo. However, the data obtained in this study
cannot exclude a pharmacokinetic / pharmacodynamic
interaction at steady-state. Concerning codeine glucuroni-
dation, our pharmacokinetic results demonstrate that in
vitro conditions studied did not necessarily reflect the in
vivo conditions at therapeutic doses. In terms of side ef-
fects, both codeine + placebo as well as codeine + di-
clofenac were well tolerated by the volunteers in our
study. Only minor side effects occurred and no rating
Figure 3
Serum concentration time profile of morphine, morphine-3-
and morphine-6-glucuronide after administration of codeine
+ placebo vs. codeine + diclofenac (Mean, SD, n= 12) 
codeine + placebo ♦  codeine + diclofenac
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Figure 4
Pain threshold after administration of codeine + placebo vs.
codeine + diclofenac, corrected to baseline at t = 0 (Mean,
SD, n= 12) ▪ codeine + placebo • codeine + diclofenac. B
Pain tolerance after administration of codeine + placebo vs.
codeine + diclofenac, corrected to baseline at t = 0 (Mean,
SD, n= 12) ▪ codeine + placebo • codeine + diclofenac
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higher than 5 was reported on a VAS scale. There are sev-
eral studies demonstrating the benefit of the combination
of NSAIDs plus opioids in comparison to opioids alone in
the treatment of postsurgical pain, pain induced by ar-
throsis and chronic pain in cancer patients. [1–7] In one
study, after a single dose of 100 mg diclofenac rectally giv-
en to postsurgical patients receiving morphine PCA, a sig-
nificant decrease in hourly morphine consumption and
plasma morphine and morphine-6-glucuronide were ob-
served after administration of diclofenac, but with a lag
time of more than 5 hours.[32]
In our study, we used the cold pressor test for analysing
the analgesic effects of opioids because it has been proven
to be sensitive to the effects of codeine and morphine in
several studies.[17,18] In contrast, this test is not appro-
priate to investigate the efficacy of NSAIDs alone.[33] In
our study, the area under the pain threshold versus time
curve and the area under the pain tolerance versus time
curve did not differ significantly after the two treatments
over the time intervals studied. In case of a pharmacoki-
netic interaction between codeine and diclofenac leading
to higher serum levels of morphine and M-6-G, an in-
crease in pain threshold and pain tolerance would have
been postulated. A placebo part of the study was omitted
because the primary objective was the assessment of a
pharmacokinetic interaction.
Because we could exclude a pharmacokinetic interaction
between codeine and diclofenac, the synergistic analgesic
effects in the above mentioned studies are likely to result
solely from the different pharmacodynamic mode of ac-
tions. Most postsurgical patients and many cancer pa-
tients have an inflammatory component to their pain,
which responds to cyclooxygenase inhibition. Further-
more, NSAIDs have been reported to have a specific effect
in malignant bone pain. [34]
Conclusions
A single dose of diclofenac does not alter the glucuronida-
tion of codeine in healthy volunteers, which is in contrast
to recent in vitro data. The formation of morphine from
codeine was not affected. The combination of codeine
and diclofenac was well tolerated.
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Table 6: Pharmacokinetic parameters of diclofenac after oral ad-
ministration of 50 mg diclofenac sodium together with 100 mg 
codeine phosphate (n = 12).
mean (95% CI)
Cmax [nmol/ml] 4.42 (3.77–5.06)
tmax [h] 1.73 (1.21–2.26)
AUC [h nmol/ml] 5.63 (4.77–6.50)
t1/2 [h] 0.97 (0.68–1.26)
Table 7: Number of subjects reporting any adverse event
codeine + placebo codeine + diclofenac
fatigue 10 8
headache 4 1
dizziness 6 5
blurred vision 3 3
nausea 2 2
itching 0 0
exanthema 0 0
others 0 0
Table 8: Mean of sum scores of all adverse events
time after drug
administration
codeine +
placebo mean ± SD
codeine +
diclofenac mean ± SD
2 h 4.3 ± 4.4 2.3 ± 2.1
4 h 1.6 ± 1.5 1.3 ± 1.7
6 h 2.9 ± 2.8 1.7 ± 1.7BMC Clinical Pharmacology 2002, 2 http://www.biomedcentral.com/1472-6904/2/2
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